Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Robert Christopher Andrade sold 106,844 shares of Fennec Pharmaceuticals stock in a transaction on Thursday, August 27th. The stock was sold at an average price of C$16.63, for a total transaction of C$1,776,815.72. Following the sale, the insider directly owned 217,675 shares of the company's stock, valued at C$3,619,935.25. This represents a 32.92% decrease in their position.
Fennec Pharmaceuticals Stock Performance
Shares of Fennec Pharmaceuticals stock opened at C$17.00 on Friday. The firm has a fifty day moving average of C$15.18 and a two-hundred day moving average of C$12.35. The stock has a market capitalization of C$596.14 million, a price-to-earnings ratio of -141.67 and a beta of 3.55. Fennec Pharmaceuticals Inc. has a 52 week low of C$7.59 and a 52 week high of C$17.64.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. acquired a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 105,000 shares of the biopharmaceutical company's stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 15.23% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
